Dismay For Argenx As J&J Pulls Out Of Lucrative Blood Cancer Pact

Ends Partnership For Cusatuzumab

The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.

regret
• Source: Alamy

European biotech argenx N.V.'s efforts to advance its clinical pipeline beyond the closely watched pipeline-in-a-product efgartigimod have hit a snag after partner Johnson & Johnson decided to walk away from a multi-million dollar pact to develop the investigational leukemia drug cusatuzumab.

The Belgian-Dutch biotech, which is listed on the Euronext and NASDAQ exchanges, teamed up with J&J's Janssen unit in December...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category